| |
Training set
|
Internal validation set
|
External validation set
|
|---|
|
Number of patients
|
148
|
485
|
511
|
|
Patient demographics
|
|
Median age (min-max)
|
58 (16–89)
|
59 (16–86)
|
68 (31–90)
|
|
Male (number, %)
|
91 (61.5%)
|
290 (59.8%)
|
270 (52.8%)
|
|
Localization
|
|
Colon
|
77 (52.0%)
|
221(45.6%)
|
379 (74.2%)
|
|
Rectum
|
71 (48.0%)
|
264 (54.4%)
|
132 (25.8%)
|
|
Stage
|
|
Stage I
|
22 (14.9%)
|
99 (20.4%)
|
106 (20.7%)
|
|
Stage II
|
64 (43.2%)
|
178 (36.7%)
|
224 (43.8%)
|
|
Stage III
|
62 (41.9%)
|
208 (42.9%)
|
181 (35.4%)
|
|
ER-α expression
|
|
High (number, %)
|
19 (12.8%)
|
78 (16.1%)
|
158 (30.9%)
|
|
Low (number, %)
|
129 (87.2%)
|
407 (83.9%)
|
353 (69.1%)
|
|
PR expression
|
|
High (number, %)
|
32 (21.6%)
| | |
|
Low (number, %)
|
116 (78.4%)
| | |
- Baseline characteristics of the two cohorts regarding demography (age and gender), tumor features (stage and localization), ER-α expression and PR expression (just in training set)
- Abbreviations: ER-α estrogen receptor –α, PR progesterone receptor
